(Q34786715)

4 August 2017

0 references

1 reference

title

The effectiveness of budesonide therapy for Crohn's disease (English)

1 reference

4 August 2017

0 references

William Jeffery Sandborn

series ordinal

3

object named as

W J Sandborn

1 reference

4 August 2017

6

B G Feagan

1 reference

4 August 2017

4

W Tremaine

1 reference

4 August 2017

S V Kane

1

1 reference

4 August 2017

P Schoenfeld

series ordinal

2

1 reference

4 August 2017

T Hofer

series ordinal

5

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Alimentary Pharmacology & Therapeutics

4 August 2017

1 reference

4 August 2017

16

1 reference

4 August 2017

1509-1517

1 reference

4 August 2017

8

1 reference

Management of Crohn's disease in adults

4 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01289.X

10.1046/J.1365-2036.2002.01289.X

21 January 2018

Identifiers

DOI

1 reference

release_geg54kfjujdy3nreveuadvwq4i

4 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/geg54kfjujdy3nreveuadvwq4i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference